Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel
Authors:
- 1 February 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (2) , 501
Abstract
PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel. PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived from four different trials and 625 patients treated with platinum from two trials were analyzed using precisely defined 50% and 75% reductions in CA-125. The standard and CA-125 response rates to paclitaxel and platinum were compared. In addition, we analyzed individual patient groups in which there was a difference in response according to the two response criteria. RESULTS: Patients with stable disease as determined by standard criteria who were treated with platinum and responded according to CA-125 criteria have an improved median progression-free survival compared with patients with stable disease who did not respond according to CA-125 criteria (10.6 v 4.8 months; P < .001). Standard and CA-125 response rates for patients treated with platinum (58.93% v 61.31%, respectively) and paclitaxel (30.65% v 31.67%, respectively) were very similar, as were rates of false-positive prediction of response by CA-125 (platinum 2.2% and paclitaxel 2.9%). Responders to paclitaxel had a significantly improved progression-free survival compared with nonresponders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P < .001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P < .001). CONCLUSION: For assessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria. We propose that they may be used as a measure of response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer. Sensitivity is maintained whether patients are treated with platinum or paclitaxel.Keywords
This publication has 25 references indexed in Scilit:
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.Journal of Clinical Oncology, 1989
- CA-125 Values Predictive of Clinical Response during Second-Line Chemotherapy for Epithelial Ovarian CancerAmerican Journal of Clinical Oncology, 1989
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomasGynecologic Oncology, 1988
- CA 125 for the monitoring of ovarian carcinoma during primary therapyInternational Journal of Gynecology & Obstetrics, 1987
- Evaluation of serum CA 125 levels in the monitoring of ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1987
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Reporting results of cancer treatmentCancer, 1981